Term
Tricyclic antidepressants: MOA |
|
Definition
-blocks the neuronal reuptake of NE or NE and 5HT
-binds to NET, SERT, DAT (not that important) |
|
|
Term
When do we start to see efficacy of TCAs? |
|
Definition
-It takes about 4-6 weeks to see clinical effects of these drug.
-this is due to the complex secondary adaptations to blockade |
|
|
Term
|
Definition
FATAL: starts out by excitation, then leads to coma, reduced respiration, and cardiac toxicity (arrithymias and tacycardia) |
|
|
Term
|
Definition
depression, nocturnal enuresis, OCD, anxiety, phobias, peripheral neuropathy |
|
|
Term
|
Definition
prevent the reuptake of indirect acting drugs (guandrel) |
|
|
Term
|
Definition
This TCA is special becuase it is similar to loxapin. This also has antipsycotic effects (can bind to D2 receptors) |
|
|
Term
Secondary adaptations to TCAs |
|
Definition
-activation at the alpha 2 receptors on the presynapse
-decrease in NE release
-densensitization
-NE returns to normal
-the expression of tyrosine hydroxylase and NET is decreased overtime
-change in sensitivity of NMDA, GABA B, 5HT 1 and 2, beta-2, alpha-1, D2
-increase in CREB and BDNF |
|
|
Term
|
Definition
Glucocorticoids decrease the levels of BDNF. When this occurs, there is a reduction in dentritic branching and a decrease in synapses between the neurons
-TCAs allow the nerves and synapses to grow, therefore an increase in branching and connections |
|
|
Term
|
Definition
-low therapeutic index
-antimuscarnic
-weight gain
-sedation through antihistamine effects: trazodone and mirtaxapine; potentiate other sedatives
-sexual dysfunction
-reduction in seizure threshold
-hypotention: orthostatic due to alpha 1: tacycardia
-cardiac effects: slowed conduction times leading to arrhythmias like class I |
|
|
Term
|
Definition
blocks the neuronal reuptake of 5HT by preferentially binding to SERT |
|
|
Term
|
Definition
agitation, nausa/vomiting, sucidal tendencies in adolescents, sexual dysfunction, akathisia
-compared to TCAs, they are much safer, and have lesser risk of AEs of TCAs
-no antihistamine effect |
|
|
Term
|
Definition
|
|
Term
|
Definition
-SSRIs are substrates and inhibitors for cyp450s: mostly for 2D6
-(fluvoxamine, fluoxetine, paroxetine > sertraline > citalopram) |
|
|
Term
Drug interactions with SSRIs |
|
Definition
Fluoxetine has a very long half life (has a active metabolite that can last 5-10 days) |
|
|
Term
Abrupt discontinuation of SSRIs |
|
Definition
|
|
Term
Secondary adaptation of SSRIs |
|
Definition
-activation at the post synapse of 5-HT receptors
-autoreceptor activation at the 5HT1 receptor on the presynapse
-desensitize of autoreceptors over weeks: serotonin returns to normal
-downregulation of post synapse
-increase in CREB and BDNF |
|
|
Term
|
Definition
-depression, anxiety, OCD, neuropathic pain, fibromyalgia |
|
|
Term
|
Definition
loss of appetite, sexual s/e, sleep disturbances
We see no muscarinic effects |
|
|
Term
Effexor, milnacipran, cymbalta: unique characteristics |
|
Definition
effexor: dose dependant inhibition of SERT, NE, and DA (low doses it is an SSRI)
-minacipran: good for fibromyalgia
-cymbalta: can cause hepatotoxicity; can also be used for neuropathic pain |
|
|
Term
|
Definition
-good for smoking sensation
-can cause agitation and seizures
-affects DA (increase)
-amphetamine like metabolites increase DA and NE |
|
|
Term
|
Definition
causes sedation because of H1 central antagonism |
|
|
Term
|
Definition
-affects the 5HT reuptake and receptors
-sedation and hepatotoxicity |
|
|
Term
|
Definition
-affects 5HT reuptake
-sedation
-priapism
***usually given at bedtime |
|
|
Term
|
Definition
deaminates NE, DA, 5HT, E and tyramine
-thought to be a housekeeping enzyme that prevents any leaky vesicles that would cause monoamines into the synapse |
|
|
Term
|
Definition
metabolizes DA and tyramine
-thought to be a housekeeping enzyme that clears out any monoamines that might go to the synapse due to leaky vesicles |
|
|
Term
Overdose of MAOi inhibitors |
|
Definition
agitation, convulsions, fever |
|
|
Term
|
Definition
-indirect acting sympathomimetics: hypertension and intrancranial bleeding
-amphetamines
-Tyramine containing foods: HTN |
|
|
Term
Characteristics of ALL antidepressants |
|
Definition
-take weeks to see clinical effects
-metabolized faster in children than younger adults
-slight dependance and withdrawal
-TCAs cause myalgia and sedation
-SSRIs: myalgia, GI, paresthesias, irritability
MAOIs: psycosis, convulsions
-wont see any effects on nondepressants |
|
|
Term
Interactions between antidepressants |
|
Definition
SSRIs or TCAs with MAOIs: 2-3 weeks apart; with fluoxetine, we should wait 5 weeks due to its long half life |
|
|
Term
Which drugs can we see serontonin syndrome due to reduction in metabolism or in combination with other drugs |
|
Definition
-MAOi
-SSRI
-TCA
-Tryptophan
-tramadol
-meperidine
-amphetamine
serotonin agonists: buspirone, triptans
-OTC dextromeophan
-Zyvox |
|
|
Term
Reversal of Serotonin syndrome |
|
Definition
cyproheptadine (5HT2 blocking activity)
-it is also an antihistamine
(Zyprexa also has 5HT2 blocking activity) |
|
|
Term
Signs and Symptoms of serotonin syndrome |
|
Definition
MILD SYMPTOMS
-akathisia
-tremors
-altered mental status
-clonus (inducible): hyperflexive
-clonus: sustained
-muscular hypertonicity (increase body movements)
- hyperthermia
SEVERE SYMPTOMS
***We will see HTN throughout this pathway
|
|
|
Term
NSAIDS and Dantrolene for Serotonin syndrome |
|
Definition
NSAIDs wont do anything and dantrolene will make the symptoms worse! |
|
|
Term
|
Definition
-treatment for mania (bipolar-mania and depression): caused by increase in Monoamines in the synapse
-MOA is unknown but thought to inhibit NE and DA release, and Increase 5HT
-also inhibits PKC and PI pathway |
|
|
Term
Adverse effects of Lithium |
|
Definition
-low therapeutic index (we can check serum levels to predict efficacy and adverse effects)
-hyponatremia can cause lithium retention (diuresis, diarrhea, NSAIDs ACEi)
-abdominal pain, polyuria, fine tremors, skin rashes (acquired diabetes insipidus, vasopression resistance)
-coma, serizures, confusion, death
-thyroid enlargement but decrease in thyroid function |
|
|
Term
Why does tyramine have an interaction with MAOi? |
|
Definition
Tyramine is like a indirect acting sympathomimetic. It increases the release of NE. In addtion, MAO inhibitors inhibit tyramine. If we inhibit tyramine, we have a continuous release of NE, which could lead to hypertension |
|
|